Biosimilar Resource Center

Reduced Out-of-Pocket Costs With Biosimilar Filgrastim for Medicare Beneficiaries

A study published in the Journal of Clinical Oncology found that Medicare beneficiaries with lung cancer who switch from reference filgrastim to the biosimilar filgrastim-sndz may have reduced out-of-pocket costs. The granulocyte-colony stimulating factor filgrastim-sndz...

BIOSIMILARS NEWS

Cost Savings With Biologic and Biosimilar Filgrastim Formulations

Granulocyte colony-stimulating factors (G-CSFs) are used to reduce the incidence, severity, and duration of febrile neutropenia (FN) in patients with cancer who are receiving...

“Nocebo” Affect and Biosimilar Discontinuation Rates

Observational studies have reported “higher-than-expected” discontinuation rates for biosimilar monoclonal antibodies related to the “nocebo” effect—the perceived induction/worsening of symptoms or loss of effect...

Study Finds Trastuzumab Biosimilar Demonstrates Equivalence in Response Rates

A randomized, double-blind study published in the British Journal of Cancer compared the treatment regimen of paclitaxel plus trastuzumab biosimilar PF-05280014 or trastuzumab sourced...

Providers Indicate Barriers to Biosimilar Uptake

In early 2018, nine biosimilars received approval from the U.S. Food and Drug Administration, yet just three had reached the market. In Europe, however,...

Global Report Predicts More Than 50% Market Growth in Monoclonal Antibody Biosimilars by 2024

The “Biosimilar Monoclonal Antibodies Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024” report indicates that the global biosimilar monoclonal antibodies...

Initiation of Biosimilar Filgrastim Within 24-72 Hours of Chemotherapy Reduces Neutropenia

A study published in Supportive Care in Cancer confirmed guideline-indicated recommendations for timing on initiating granulocyte colony-stimulating factors (G-CSFs) to management chemotherapy-induced neutropenia (CIN)...

Study Shows Cost Savings with Biosimilar Rituximab

A study presented at the 2018 American Society of Hematology Annual Meeting found that the use of an intravenous (IV) rituximab biosimilar resulted in...
click me